Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Abhinav V. Reddy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9209-2923; OpenAlex author ID A5038945187, A5071226855. Sources: OpenAlex.

Their work

Papers
15 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2021: 2 papers · 2022: 8 papers · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 15

  1. Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Early-Onset Pancreatic Cancer: Clinical Outcomes and Toxicity. First author DOI 10.1016/j.ijrobp.2022.07.1120↗
  2. Upregulated expression of PTTG1 is associated with progression of pancreatic cancer. Co-author DOI 10.21037/jgo-23-979↗
  3. Solute carrier family 16 member 1 as a potential prognostic factor for pancreatic ductal adenocarcinoma and its influence on tumor immunity. Co-author DOI 10.21037/jgo-24-147↗
  4. Effectiveness of the nutrition referral system in a multidisciplinary pancreatic cancer clinic. First author DOI 10.1007/s00520-023-07795-3↗
  5. The Timing of Surgery Following Stereotactic Body Radiation Therapy Impacts Local Control for Borderline Resectable or Locally Advanced Pancreatic Cancer. First author DOI 10.3390/cancers15041252↗
  6. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients trea… Co-author DOI 10.1002/cam4.4527↗
  7. Efficacy and Safety of Reirradiation with Stereotactic Body Radiation Therapy for Locally Recurrent Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.clon.2021.12.014↗
  8. Location, Location, Location: What Should be Targeted Beyond Gross Disease for Localized Pancreatic Ductal Adenocarcinoma? Proposal of a Standardized Clinical … Co-author DOI 10.1016/j.prro.2022.01.005↗
  9. A safety study of intraoperative radiation therapy following stereotactic body radiation therapy and multi-agent chemotherapy in the treatment of localized pan… Co-author DOI 10.1186/s13014-022-02145-9↗
  10. High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resecta… Co-author DOI 10.21037/jgo-21-513↗
  11. Stereotactic body radiation therapy for the treatment of locally recurrent pancreatic cancer after surgical resection. Co-author DOI 10.21037/jgo-22-38↗
  12. Upfront Chemotherapy Followed by Stereotactic Body Radiation Therapy with or without Surgery in Older Patients with Localized Pancreatic Cancer: A Single Insti… Co-author DOI 10.3390/curroncol29010028↗
  13. Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and s… Co-author DOI 10.3857/roj.2021.01060↗
  14. Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy. Co-author DOI 10.1186/s13014-021-01969-1↗
  15. Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemot… Co-author DOI 10.3857/roj.2021.00815↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin Peng He · 13 shared papers, 2021–2026 · strength 2.16
  2. Colin Hill · 13 shared papers, 2021–2026 · strength 2.16
  3. Amol Kumar Narang · 13 shared papers, 2021–2026 · strength 2.16
  4. Joseph M. Herman · 12 shared papers, 2021–2026 · strength 1.96
  5. Shuchi Sehgal · 11 shared papers, 2021–2026 · strength 1.79
  6. Jeffrey John Meyer · 11 shared papers, 2021–2026 · strength 1.79
  7. Lei Zheng · 10 shared papers, 2021–2023 · strength 1.57
  8. Amy Hacker‐Prietz · 3 shared papers, 2021–2023 · strength 0.41
  9. Timothy A. Lin · 2 shared papers, 2023 · strength 0.35
  10. Yu He · 1 shared paper, 2024 · strength 0.28
  11. Peiguo Cao · 1 shared paper, 2024 · strength 0.28
  12. Ana De Jesus‐Acosta · 2 shared papers, 2022 · strength 0.27
  13. Daniel A. Laheru · 2 shared papers, 2022 · strength 0.27
  14. Meng Wang · 1 shared paper, 2024 · strength 0.20
  15. Shinichi Ikuta · 1 shared paper, 2024 · strength 0.20
  16. Alice Talbot · 1 shared paper, 2024 · strength 0.20
  17. Wenna Jiang · 1 shared paper, 2024 · strength 0.20
  18. Li Ren · 1 shared paper, 2024 · strength 0.20
  19. Sydnee Wong · 1 shared paper, 2023 · strength 0.17
  20. Atif Zaheer · 1 shared paper, 2022 · strength 0.15
  21. Ding Ding · 1 shared paper, 2021 · strength 0.13
  22. Dung Thi Le · 1 shared paper, 2022 · strength 0.12
  23. William R. Burns · 1 shared paper, 2022 · strength 0.12
  24. Valerie Lee · 1 shared paper, 2022 · strength 0.12
  25. Christopher L. Wolfgang · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.